Adult Immunization

People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.

Robert Hopkins, Jr, MD, NFID medical director, details a range of resources on the foundation's website including in-depth vaccine recommendations, live webinars, plus much more.

The 2 novel vaccine candidates each combine a Sanofi licensed influenza vaccine with the Novavax adjuvanted recombinant COVID-19 vaccine.

The National Foundation for Infectious Diseases medical director appeals to the community at large to set politics and personal grievance aside and to "first, do no harm."

Your daily dose of the clinical news you may have missed.

Guidance from the Advisory Committee on Immunization Practices on best practices for COVID-19 vaccination continues to evolve, Hopkins explained.

Under risk-based guidelines, less than 30% of eligible adults are vaccinated against pneumococcal disease, said Robert Hopkins, Jr, MD. More details, here.

Your daily dose of the clinical news you may have missed.

Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.

Little action has been taken by state medical boards against clinicians who spread unsubstantiated claims about COVID-19, vaccines, or other pandemic-related topics.

The FDA cleared Novavax to start enrolling the planned phase 3 trial after a safety concern was found to be unrelated to the combination vaccine.

Find details on the surge in US pertussis cases, the first self-administered flu vaccine, and study findings underscoring the evolving nature of long COVID.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.

CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.

The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.

IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.

IDWeek2024: The nanoparticle influenza vaccine and combination flu-Covid-19 shot produced immunogenicity comparable to or higher than comparator vaccines.

V116 (CAPVAXIVE™) covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases in adults aged 50 years and older.

Essential health screenings and immunizations are declining among US adults. A new survey identified 7 issues that help drive the reduced rates.

IDWeek 2024: Black individuals were less likely to be vaccinated against all 3 respiratory viruses than White individuals, according to new research.

Older adults hospitalized with RSV were older, more frail, and more likely to have respiratory comorbidities than those with influenza A or B, the study found.

Adults saying they don't need immunization this fall have received the vaccines in the past, survey authors report, suggesting a lingering misinformation effect.

Your daily dose of the clinical news you may have missed.

New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.

Immune responses for both vaccines were noninferior when given at the same visit compared with separate administration among adults aged 50 years and older.

The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.